Podcast on Ovarian Stimulation in IVF

Kapitoly

Een race met maar één winnaar

Selectie, dominantie en het standaardlot

De drie sleutelbegrippen: Drempel, Venster, Atresie

De onmisbare rol van LH

Wat stimulatie moet bereiken

The Old School: Long Agonist

The New Standard: Antagonist

Other Ways to Suppress

Getting in Sync

The Final Step: Triggering

Supporting the Luteal Phase

Personalising the Protocol

A Practical Dosing Guide

Monitoring the Cycle

When Things Go Wrong

The Split Cohort Signature

Take-Homes and Final Thoughts

Přepis

Dan: Stel je een race voor waar vijftien deelnemers aan de start verschijnen, maar het parcours zo is ontworpen dat er maar één kan finishen. De andere veertien vallen gegarandeerd uit. Klinkt heftig, hè? Nou, die race vindt elke maand plaats in het menselijk lichaam.

Emma: Dat is een perfecte manier om het te omschrijven, Dan. En het is de kern van de fysiologie van de eierstokken. Het is geen fout in het systeem, het is precies hoe het ontworpen is.

Dan: En dat is waar we vandaag induiken. U luistert naar de Studyfi Podcast. Emma, onze expert, help ons eens. Wat gebeurt er precies in die race?

Emma: Zeker. Het hele proces heeft vier fases: rekrutering, selectie, dominantie en atresie. Het klinkt als een seizoen van een realityshow, en eerlijk gezegd is het niet heel anders.

Dan: De Follikel Games! Ik snap het. Wat is de eerste fase, rekrutering?

Emma: Dat is het startschot. Aan het einde van de vorige cyclus zorgt een stijging van het hormoon FSH ervoor dat een groep van ongeveer vijftien follikels—dat zijn de blaasjes waarin eicellen zitten—uit een rustende voorraad wordt 'gerekruteerd' om mee te doen aan de race van deze maand.

Dan: Oké, dus we hebben een team van vijftien follikels aan de startlijn. Wat gebeurt er dan?

Emma: Dan komt de selectie. Terwijl de follikels beginnen te groeien, daalt het FSH-niveau weer. En hier is de truc: één follikel is net iets gevoeliger voor FSH dan de rest. Die heeft een lagere 'drempel', zou je kunnen zeggen.

Dan: Dus die ene kan blijven groeien, zelfs als er minder 'brandstof'—minder FSH—is?

Emma: Precies! Die ene follikel schiet vooruit en wordt dominant. En dan wordt 'ie een beetje een diva. Hij begint zelf hormonen te produceren, zoals oestradiol en inhibine, die het FSH-niveau nóg verder onderdrukken.

Dan: Wacht even, dus de winnaar zorgt er actief voor dat de concurrentie geen schijn van kans meer heeft? Dat is genadeloos!

Emma: Absoluut! En dat leidt ons naar de laatste fase: atresie. Dat is de medische term voor het afsterven en verschrompelen van de andere veertien follikels. Ze krijgen gewoon niet genoeg FSH om te overleven en verdwijnen. Dat is hun standaardlot.

Dan: Wow. Dus atresie is niet iets slechts of een ziekte, het is de normale gang van zaken. Dat is een belangrijk punt.

Emma: En het is de sleutel tot het begrijpen van ovariële stimulatie bij vruchtbaarheidsbehandelingen. We 'creëren' geen nieuwe follikels; we voeren een reddingsmissie uit. We redden die andere veertien van hun standaardlot, atresie.

Dan: Je noemde net al het woord 'drempel'. Ik hoor ook vaak de term 'venster'. Kun je die twee, samen met atresie, nog eens helder uitleggen?

Emma: Goede vraag. Dit zijn de drie concepten die je echt moet onthouden. Ten eerste, de **drempel**. Elke follikel heeft zijn eigen specifieke FSH-gevoeligheid. Zie het als de minimale lengte die je moet hebben voor een achtbaan. De follikel met de laagste drempel, de minst 'kieskeurige', wint.

Dan: Logisch. En het venster?

Emma: Het **venster** is een eigenschap van de cyclus, niet van de follikel. Het is de periode waarin het FSH-niveau boven die drempel van de follikels uitkomt. In een natuurlijke cyclus is dat venster maar kort. De FSH-spiegel daalt snel, waardoor het venster sluit voor de meeste follikels.

Dan: En dan... atresie.

Emma: Exact. **Atresie** is wat er gebeurt als het venster sluit voordat een follikel de eindstreep heeft gehaald. Het is het standaardpad. Dus om samen te vatten: de drempel is hoe gevoelig een follikel is, het venster is hoe lang er genoeg brandstof is, en atresie is het einde van de rit voor de meesten.

Dan: Dat is super duidelijk. Dus bij stimulatie proberen we dat 'venster' eigenlijk kunstmatig langer open te houden?

Emma: Precies! We geven van buitenaf extra FSH, waardoor het niveau hoog blijft. Zo kunnen veel meer follikels—ook die met een hogere drempel—boven hun drempel blijven en meegroeien. We redden ze van atresie.

Dan: Oké, FSH is dus de superster als het gaat om follikelgroei. Maar er is nog een ander belangrijk hormoon, toch? LH.

Emma: Zeker, LH speelt drie cruciale rollen. Zonder LH gebeurt er heel weinig. Ten eerste, LH is nodig voor de productie van het 'ruwe materiaal'. Het stimuleert speciale cellen, de thecacellen, om androgenen te maken.

Dan: En wat doen de follikels daarmee?

Emma: Nou, de granulosacellen in de follikel—die door FSH worden gestimuleerd—pakken die androgenen en zetten ze met een proces genaamd aromatisering om in oestradiol. Het is een tweestapsfabriek: LH start de productielijn, FSH voltooit het product. Geen LH, geen oestradiol.

Dan: Helder. Wat is de tweede rol?

Emma: Als follikels groter worden, zorgt FSH ervoor dat ze ook receptoren voor LH ontwikkelen. Dat betekent dat ze in een later stadium direct op LH kunnen reageren voor hun groei. Ze worden als het ware tweetalig.

Dan: En de derde rol is de meest dramatische, neem ik aan?

Emma: Absoluut! Dat is de LH-piek, of 'the surge'. Dit is een enorme golf van LH die de laatste eicelrijping in gang zet, de eisprong triggert en de follikel omvormt tot het corpus luteum, het geellichaam. Bij een IVF-behandeling vervangen we deze natuurlijke piek door een 'trigger'-medicijn, zodat we zelf de controle hebben over het moment van de eisprong.

Dan: Dus als we de natuurlijke cyclus omzetten in een gestimuleerde cyclus, wat zijn dan de hoofddoelen? Je noemde al het openhouden van het FSH-venster.

Emma: Dat is inderdaad doel nummer één: het FSH-venster verbreden. Zo redden we meer follikels van atresie. Maar er zijn er nog drie.

Dan: Ik ben benieuwd.

Emma: Ten tweede, en dit is cruciaal: we moeten een vroegtijdige, spontane LH-piek voorkomen. Als het lichaam zelf een LH-piek maakt midden in de stimulatie, vindt er een eisprong plaats en zijn we alle eicellen kwijt. De hele cyclus is dan verloren.

Dan: Oei, dat wil je absoluut niet. En nummer drie?

Emma: Het derde doel is om die LH-piek op een door ons gekozen moment te vervangen. We gebruiken een trigger-medicijn om de eisprong precies te timen, zodat we de eicelpunctie perfect kunnen plannen.

Dan: En de laatste?

Emma: Het vierde doel is het ondersteunen van de luteale fase, de periode na de eisprong. De stimulatie verstoort de hormoonbalans, waardoor het lichaam soms niet genoeg ondersteuning biedt voor een eventuele zwangerschap. Dus als er een verse terugplaatsing is, geven we extra ondersteuning. Bij een 'freeze-all'-cyclus is dat niet nodig.

Dan: Fantastisch. Dus het is een zorgvuldig georkestreerd proces om de natuur een handje te helpen en de uitkomst te maximaliseren. Heel fascinerend.

Dan: So we've got our FSH to grow the follicles. But Emma, you mentioned something crucial before. We can't let the body just ovulate on its own timeline. How do we prevent a premature surge of that luteinizing hormone, or LH?

Emma: That's the million-dollar question, Dan. And the answer is surge suppression. We have to take control of the cycle. For a long time, the standard method was the long agonist protocol.

Dan: Long agonist. That sounds... long.

Emma: It is! You're not wrong. With this protocol, we'd actually use a GnRH agonist to first cause a big release of hormones, and then... it completely desensitizes the pituitary. It downregulates it, basically putting it to sleep for a couple of weeks.

Dan: So you shut the system down before you even start stimulating with FSH?

Emma: Exactly. It gives us incredible control over scheduling, and the response is very predictable. We used to use it a lot, especially for patients with endometriosis to calm things down first.

Dan: It sounds pretty solid. Why isn't it the default anymore?

Emma: A few big reasons. It's a long protocol with way more injections. Patients often get menopausal symptoms like hot flashes during that downregulation phase, which isn't fun. But the biggest issue is a much higher risk of Ovarian Hyperstimulation Syndrome, or OHSS.

Dan: And that's the one we really want to avoid.

Emma: Absolutely. With the long agonist protocol, you can't use a safer trigger option. You're locked in. So it's used more selectively now, maybe after other protocols have failed.

Dan: So what's the new champion? What's the protocol we see most often today?

Emma: That would be the antagonist protocol. It's the current default in most clinics, and for good reason.

Dan: Okay, lay it on me. Why did it win?

Emma: It's just... simpler and safer. It's a much shorter protocol, which means fewer injections. Patients are happier. But the strongest argument, the knockout punch, is that it dramatically lowers the risk of OHSS.

Dan: How does it do that?

Emma: Because with an antagonist protocol, we can use what's called an agonist trigger to mature the eggs. It's a much gentler, shorter signal. We'll get to triggers in a bit, but this flexibility is the key safety feature.

Dan: Shorter, fewer injections, safer... this sounds too good to be true. Is there a catch?

Emma: There's always a catch, isn't there? The antagonist drugs work by blocking the GnRH receptor, which stops the LH surge. But it also subtracts some of the body's own, endogenous FSH along with the LH.

Dan: Ah, so it's not quite as targeted as we'd like?

Emma: Precisely. Now, if we're using a generous starting dose of FSH, this little dip doesn't really matter. But if a clinic is being very conservative with the dose, subtracting that endogenous bit can cause some of the smaller, higher-threshold follicles to drop out of the race.

Dan: So the antagonist is like a bouncer at a club. It's there to kick out the rowdy LH, but sometimes it accidentally kicks out LH's quiet friend, FSH, too.

Emma: That is a perfect analogy! Yes, and if the party inside isn't very lively to begin with, you'll definitely notice his absence.

Dan: Okay, so agonist and antagonist are the big two. Are there any other, let's say, niche players in the surge suppression game?

Emma: There are! Two others worth knowing are PPOS and the microdose flare. PPOS stands for Progestin-Primed Ovarian Stimulation.

Dan: Progestin... like the hormone in birth control?

Emma: The very same. In PPOS, the patient takes an oral progestin pill right from day one of stimulation. It's cheap, it's simple, and there are no extra injections for suppression. It works great at preventing the LH surge.

Dan: That sounds fantastic! Why not just use that all the time?

Emma: Because the progestin completely wrecks the endometrium for a fresh transfer. The lining just isn't receptive. So PPOS is strictly for cycles where you plan to freeze all the embryos from the start.

Dan: Got it. Freeze-all only. And what about the microdose flare?

Emma: That's more of a rescue protocol, often for patients who are predicted to be poor responders. We use tiny doses of an agonist. Initially, it gives a little 'flare' of the body's own FSH to help recruitment, and then it settles into its suppression effect.

Dan: Alright. So once we've chosen our suppression strategy, do we just... start? Or is there a prep phase?

Emma: Good question. Often, there's a pre-stimulation phase to synchronize the follicles. The goal is to get the whole cohort of antral follicles to a similar starting line before the race begins.

Dan: So everyone leaves the blocks at the same time.

Emma: Exactly. The most common way is using a standard oral contraceptive pill for two or three weeks. It's fantastic for clinic scheduling. But... some data suggests it might slightly reduce the final oocyte count in antagonist cycles. It's probably a real effect, but a small one.

Dan: What are the other options?

Emma: For some patients, especially poor responders, we might use estradiol priming in the luteal phase of the cycle before stimulation. It helps suppress that early FSH rise and can really tighten up the cohort.

Dan: So it's more about quality control of the follicle group.

Emma: Yes. And then there are even more flexible options like a 'random start'. We just... start stimulation, regardless of the day of the cycle. This is common in oncofertility where time is critical. It works because follicle growth isn't as strictly tied to cycle day as the old textbooks made us believe.

Dan: Okay, so we've grown the follicles, we've suppressed the surge... now we have to tell them it's go-time. Let's talk about the trigger shot.

Emma: The final and most critical step before egg retrieval! The trigger does the job of the natural LH surge, which is final oocyte maturation. We have three main options here.

Dan: Let's hear them.

Emma: First, there's hCG, human chorionic gonadotropin. It acts just like LH but has a really long half-life, around 36 hours. It's very effective at maturing the eggs.

Dan: But that long half-life sounds like it could be a problem.

Emma: It is. It's the main driver of OHSS because it keeps stimulating the ovaries long after the eggs are retrieved. So, highest OHSS risk.

Dan: What's option two?

Emma: Option two is the agonist trigger we mentioned, like buserelin. This causes the body to release its own, natural surge of LH and FSH. The beauty is that this surge is powerful but short-lived—it's gone in about 24 hours.

Dan: And that's why it's safer?

Emma: Exactly! It's the lowest risk for OHSS. But... because the hormonal support vanishes so quickly, the luteal phase is severely insufficient. This means fresh transfers don't work well. An agonist trigger is almost always paired with a freeze-all approach.

Dan: And the third option?

Emma: A dual trigger. This is a combination of an agonist trigger plus a small dose of hCG. The idea is to get the safety benefits of the agonist while providing just enough hCG to support a fresh transfer. The evidence is a bit thinner than the enthusiasm for it, and the OHSS protection is only partial.

Dan: That makes sense. The trigger choice seems directly linked to what happens *after* the retrieval. This must be why luteal phase support is so important.

Emma: It's absolutely mandatory. In any stimulated cycle, the high hormone levels mess with the corpus luteum function. And if you use an agonist trigger, you basically have no corpus luteum to speak of. Without support, the progesterone would fall and you'd lose the pregnancy.

Dan: So what's the standard support?

Emma: The gold standard for a long time has been vaginal progesterone—things like Crinone or Endometrin. It delivers progesterone directly to the uterus. Increasingly, though, we're seeing oral dydrogesterone, which studies show is just as effective and much more convenient for the patient.

Dan: Is there anything else?

Emma: Historically, doctors would give small, repeated injections of hCG to support the luteal phase. It works, but as you can guess, it just brings back that high risk of OHSS. So you'll rarely see that in a fresh cycle anymore.

Dan: So once a patient is pregnant, how long do they have to stay on this support?

Emma: Typically until about 8 to 10 weeks of gestation. That's when the placenta has fully developed and takes over progesterone production. It's called the luteal-placental shift.

Dan: Okay, that makes a lot of sense. So, we've covered the different strategies for controlling the cycle. Now, I imagine the next big question is... how do we actually decide what to do for an individual patient?

Dan: Okay, so that covers the basics of the drugs. But I hear the word 'personalisation' thrown around a lot. Is it really the magic bullet for IVF success?

Emma: That's such a great question, Dan. And the answer is... sort of. It's not magic, but it is important. Think of it less as a magic bullet and more as a safety feature.

Dan: A safety feature? What do you mean?

Emma: Well, two big studies, ESTHER-1 and OPTIMIST, looked at algorithm-driven dosing. They tried to perfectly personalize the drug dose for each patient.

Dan: And did it boost success rates through the roof?

Emma: Here's the surprising part... not really. The average success rate, what we call the cumulative live birth rate, barely moved at all.

Dan: Wait, so what's the point then? Why go to all that trouble?

Emma: Because it reduces the extremes. With personalised dosing, you get fewer poor responders who get no eggs. And you get fewer hyper-responders who are at risk for OHSS. It basically pulls everyone closer to the middle.

Dan: Ah, so it's not about making the average outcome better, it's about preventing the really bad outcomes. It moves the tails of the distribution, not the mean.

Emma: Exactly! So if someone is selling a personalised algorithm promising a huge boost in your overall success rate... the evidence just isn't there yet. The real win is in safety and consistency.

Dan: Okay, that makes sense. So can you walk me through what a practical, personalised plan looks like? How do you decide the starting dose?

Emma: Definitely. The most common way is to base it on the patient's AMH level, which tells us about their ovarian reserve.

Dan: AMH... anti-müllerian hormone, right?

Emma: That's the one. So let's break it down. If a patient has a very high AMH, say over 30, we'd start with a low dose, maybe 100 to 125 units. We expect a lot of eggs, so we don't need to push hard.

Dan: And if their reserve is lower?

Emma: Right. For someone with a reduced reserve, an AMH between 5 and 15, we'd start much higher—maybe 225 to 300 units. For a very reduced reserve, under 5, you'd likely just start at 300.

Dan: So you're matching the engine power to the size of the car, essentially.

Emma: That's a perfect analogy! Now, there's a little nuance. Sometimes, even with a high-reserve patient, we might use a higher dose if the goal is to maximize the number of eggs for freezing. It's a trade-off... a bigger cohort of eggs, but a higher risk of OHSS.

Dan: So you've picked a dose and started the injections. You don't just set it and forget it, right? What are you looking for during the cycle?

Emma: Not at all! Monitoring is key. A few days in, we do the first scan and blood test. We're checking the initial response—are the follicles growing? Is the estrogen level rising? This tells us if we're on target.

Dan: And what else?

Emma: We track the growth of the whole group of follicles, what we call the cohort. We're watching the lead follicle, because its size determines when we trigger ovulation. And we're keeping an eye on progesterone levels to make sure they don't rise too early.

Dan: Sounds like there are a lot of moving parts. How many decisions are you actually making during that time?

Emma: It boils down to about four key decisions. First, do we need to cancel the cycle? This might be due to a poor response or a safety concern.

Dan: Okay, what's the second?

Emma: Second, do we modify the dose? Honestly, we do this sparingly. The evidence for changing the dose mid-stream is pretty weak. Third, when do we start the antagonist drug? And fourth, the big one: when to trigger.

Dan: So let's talk about when things don't go according to plan. I have a scenario for you. A 33-year-old patient, good AMH of 28... but she only gets three mature oocytes. What happened?

Emma: Ah, the classic diagnostic puzzle. This is where an embryologist has to be a detective. There are usually four potential culprits, and they're all variations of the same theme: the follicles didn't get enough FSH for long enough.

Dan: Okay, lay them on me. What's culprit number one?

Emma: The starting dose was just too low. The FSH window never opened wide enough to recruit all the follicles that were available.

Dan: Makes sense. Number two?

Emma: The antagonist drug. Remember how it suppresses the pituitary? Well, it also subtracts a little from the overall FSH signal. If the dose was already conservative, that little dip can be enough to lose some follicles.

Dan: And the last two?

Emma: You could have a late-follicular dose drop, where the dose is reduced near the end, effectively closing the window on smaller follicles. Or, number four, the trigger was just too early. The lead follicles were ready, but the rest of the group hadn't caught up.

Dan: So how would you spot this happening?

Emma: There's a signature pattern you can often see on the ultrasound. We call it a 'split cohort'. You'll see two distinct groups of follicles—a few big leaders, and then a separate cluster of smaller ones, with a gap in between.

Dan: So you're forced to choose which group to sacrifice.

Emma: Exactly. If you trigger for the big ones, you lose the little ones to immaturity. If you wait for the little ones, the big ones become over-mature. By the time you see that split, the cycle is already compromised.

Dan: Wow. Can you fix it?

Emma: You can! I have a great case in mind. A 33-year-old with a super high AMH. First cycle on an antagonist protocol, they got 15 oocytes, but only 3 were mature. Zero embryos to use.

Dan: Devastating.

Emma: Truly. So for the next cycle, the only change was the protocol. They switched to an agonist protocol and a slightly higher FSH dose. This time, they got 11 oocytes, but 10 were mature. They ended up with five high-quality blastocysts.

Dan: Same patient, same lab... totally different outcome just by changing the stimulation.

Emma: That's the key takeaway. It wasn't 'bad eggs'. It was a stimulation phenotype. The protocol wasn't the right fit for her physiology.

Dan: This has been incredibly insightful, Emma. So, as we wrap up, what are the big take-home messages for our listeners?

Emma: I think there are four main points. First, a protocol is a set of tradeoffs, not a perfect recipe. There's always a balance between goals and risks.

Dan: Right. And second was about personalisation.

Emma: Yes. Personalisation is about safety and avoiding extreme outcomes. It moves the tails, not the mean. Don't expect it to double your success rate overnight.

Dan: Got it. What's number three?

Emma: When a good-prognosis patient gets a poor outcome, it usually has a correctable cause. We need to investigate the stimulation before just blaming the patient's eggs.

Dan: That leads perfectly into the last point, which is about that blame game.

Emma: It does. The stimulation protocol has the most levers we can pull to change an outcome. So as embryologists and clinicians, when a cycle fails, the first place we should look for answers is the stimulation chart.

Dan: Fantastic. Well, that brings us to the end of our journey through the IVF lab, from gametes all the way to clinical application. Emma, thank you so much for sharing your expertise with us.

Emma: It's been an absolute pleasure, Dan. I hope it's been helpful for everyone listening.

Dan: I'm sure it has. To all our listeners, thanks for tuning into the Studyfi Podcast. Keep studying, stay curious, and we'll see you next time.